BlackRock’s AbbVie ABBV Stock Holding History

BlackRock’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-240,000	Closed	-$38.8M	–	5561
2022 Q4	$38.8M	Buy	+240,000	New	+$36.8M	﹤0.01%	2644

Other funds holding ABBV

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock's ABBV Position: Q1 2026 in Review

BlackRock reduced its AbbVie (ABBV) stake by 0.32% in Q1 2026, selling an estimated $106M and leaving 150,698,125 shares worth $32.8B. The position accounts for 0.57% of the portfolio, ranked #22.

BlackRock first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $34.5B in Q4 2025. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

BlackRock held 150,698,125 shares of AbbVie worth $32.8B as of Q1 2026.
BlackRock sold 476,418 AbbVie shares in Q1 2026, an estimated $106M.
AbbVie made up 0.57% of BlackRock's portfolio in Q1 2026, its #22 holding.
BlackRock first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
BlackRock's AbbVie position peaked at $34.5B in Q4 2025.
4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.